Search

Displaying results 8461 - 8470 of 8515 in total
  1. Drug

    Ramosetron

    go.drugbank.com/drugs/DB09290
    Investigational

    It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.

  2. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small

  3. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

  4. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    As of May 2013 no new trials had been registered.

  5. Drug

    Lecithin, soybean

    go.drugbank.com/drugs/DB14161
    Investigational

    complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as

  6. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.

  7. Drug

    Tefidsogene civaparvovec

    go.drugbank.com/drugs/DB16789
    Investigational

    Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.

  8. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  9. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  10. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.